ABA 201
Alternative Names: ABA-201Latest Information Update: 08 Sep 2023
At a glance
- Originator Abata Therapeutics
- Class Antihyperglycaemics; Gene therapies; T lymphocyte cell therapies
- Mechanism of Action Regulatory T-lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Type 1 diabetes mellitus
Most Recent Events
- 24 Aug 2023 Preclinical trials in Type 1 diabetes mellitus in USA (Parenteral), prior to August 2023
- 24 Aug 2023 Pharmacodynamics data from a preclinical trial in Type 1 diabetes mellitus released by Abata Therapeutics
- 24 Aug 2023 Abata Therapeutics plans a First-in human clinical trial for Type 1 diabetes mellitus in 2025